Oliver Luxxe Assets’s Gilead Sciences GILD Stock Holding History

Oliver Luxxe Assets’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.68M	Sell	52,852 -306	-0.6%	-$40.3K	0.98%	36
2026 Q1	$7.41M	Sell	53,158 -13,630	-20%	-$1.91M	1.11%	24
2025 Q4	$8.2M	Buy	66,788 +744	+1%	+$90.4K	1.25%	23
2025 Q3	$7.33M	Buy	66,044 +3,579	+6%	+$407K	1.16%	24
2025 Q2	$6.93M	Buy	62,465 +3,156	+5%	+$336K	1.24%	19
2025 Q1	$6.65M	Buy	59,309 +10,991	+23%	+$1.13M	1.23%	19
2024 Q4	$4.46M	Buy	+48,318	New	+$4.35M	0.39%	86
2016 Q1	–	Sell	-4,821	Closed	-$405K	–	82
2015 Q4	$405K	Buy	+4,821	New	+$502K	0.36%	76

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Oliver Luxxe Assets's GILD Position: Q2 2026 in Review

Oliver Luxxe Assets reduced its Gilead Sciences (GILD) stake by 0.58% in Q2 2026, selling an estimated $40.3K and leaving 52,852 shares worth $6.68M. The position accounts for 0.98% of the portfolio, ranked #36.

Oliver Luxxe Assets first reported a position in GILD in Q4 2015 and has held it in 8 quarters since. The position peaked at $8.2M in Q4 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Oliver Luxxe Assets held 52,852 shares of Gilead Sciences worth $6.68M as of Q2 2026.
Oliver Luxxe Assets sold 306 Gilead Sciences shares in Q2 2026, an estimated $40.3K.
Gilead Sciences made up 0.98% of Oliver Luxxe Assets's portfolio in Q2 2026, its #36 holding.
Oliver Luxxe Assets first reported a position in Gilead Sciences in Q4 2015 and has held it in 8 quarters since.
Oliver Luxxe Assets's Gilead Sciences position peaked at $8.2M in Q4 2025.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Oliver Luxxe Assets's 13F filing for Q2 2026, filed 9 Jul 2026.